Genetic enhancement of radionuclide cancer therapy.
Wheldon
T E
TE
Mairs
R J
RJ
Boyd
M
M
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001246:Astatine / Q000627:therapeutic use; D002352:Carrier Proteins / Q000235:genetics; D015316:Genetic Therapy; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D009638:Norepinephrine / Q000235:genetics; D050484:Norepinephrine Plasma Membrane Transport Proteins; D011868:Radioisotopes / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D027981:Symporters; D014162:Transfection
D000970:Antineoplastic Agents; D002352:Carrier Proteins; D006146:Guanidines; D050484:Norepinephrine Plasma Membrane Transport Proteins; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C493227:SLC6A2 protein, human; D027981:Symporters; C078685:1-(3-astatobenzyl)guanidine; D019797:3-Iodobenzylguanidine; D009638:Norepinephrine; D001246:Astatine